Professional Documents
Culture Documents
Science Conference
rd
February 2001
TM
Agenda
Project Overview
The potential
The challenge and the action plan
Febtuary 2001
TM
Decision
Architects
Monitor
Clipper
Partners
M2C
M.A.S.T.
Activities
Processes &
Systems
Marketspace
Center
(E-Commerce)
Corporate
Finance
Monitor
Institute
Monitor
University
Febtuary 2001
TM
Febtuary 2001
TM
Government
Factor
Conditions
Demand
Conditions
Related and
Supporting
Industries
Factor quality
Factor specialization
Febtuary 2001
TM
Israel Research
International
Research
Profiled global industry trends and mapped them against the cluster
activities in Israel
Agenda
Project Overview
The Potential
The Challenge and the action plan
Febtuary 2001
TM
120
100
80
Bn$
60
40
20
Bioinformatics, pharmocogenomics
Agricultural Biotechnology
Strong demand for insect-protected and herbicidetolerant crops
Recent shift towards products with enhanced output traits
Diagnostic
Therapy selection and monitoring utilizing
genetic data
Industrial Biotechnology
The pulp and paper industry
0
2004
2010
Source: Consulting Resources Inc, 1998; Business (02/2000); Frost & Sullivan ; Biotechnology Industry Organization
Febtuary 2001
TM
1200
2000
U.S.
EU + Switz.
UK
1,041
1600
800
1200
715
668
557
M$
Index
646
452
800
400
347
251
400
183
118
0
-01
-00
-00
-99
-99
-98
-98
-97
-97
-96
-96
-95
-95
-94
-94
Febtuary 2001
TM
110
29
49
118
47
Israel Potential
High quality academic research
Skilled human resources - over 1,700 graduates every
year in related fields
Academic research and industrial R&D in key industry
segments (e.g. cancer, immunology, bio-informatics, etc.)
Industrial success - growing sector with recently successful
IPOs (e.g. XTL, Compugen, Keryx).
Potential for the future: interdisciplinary areas
Febtuary 2001
TM
Israel Cluster
Relative
Activity in
Future
Development*
~$10B
18%
$8.8B
12%
$5.5B
~$5B
43%
$1B
Bioinformatics
Cancer
~$1B
Autoimmune
17%
$1.2B
4%
$1.3M
Infectious
Diseases
108%
$1.4B
22%
$3.1B
Cardiovascular
Diagnostics
0%
10%
20%
% of academia
research projects and
products developed in
industry:
Therapeutic
areas
Pharmocogenomics
30%
40%
Platform
technology
110%
Agro-biotech
Febtuary 2001
TM
Febtuary 2001
TM
15,000
14000
1870
1,500
200
175
11000
10,000
160
9000
1,000
130
760
5,000
500
0
1994
1996
1999
100
500
0
1994
1996
1999
Source: Ernst & Young; OST Report on the UK Biotech Cluster, Aug 1999; Northwest Biotech Development Study (June 98); ERBI BioBusiness Trends 99
Report; Speech by Lord Sainsbury, August 1999
Febtuary 2001
TM
Agenda
Project Overview
The Potential
The Challenge and the action plan
Febtuary 2001
TM
market capitalization
Market Capitalization of
Public Companies, 2000*
150
1,274
Sales
1,200
Employees
264.0
Israel
USA
120
120
15
300
210.0
200
900
90
10
17.5
600
60
50
5
275
300
23
6.7
144
100
0
US
UK
Israel
2.1
0
US
UK
Israel
Source: Harry Langbeheim; NBC; Press release; Interviews; Ernst & Young Life Science Report, 1999 & 2000
Febtuary 2001
TM
93.0 97.0
30
2.6
0
83.0
0
1996
1997
1998
1999
2000
2000
Academia
Institute of
Biotechnology
Univeler Research Ltd
John Innes Research
Center
Government
Government Office
for the East
East of England
Investment Agency
County Council
Biotech Companies
CeNes
CTBL Ltd
Cambridge Drug
Discovery
Service
Companies
Reddie & Grose
Patent Agents
Barclays
Bank
Weil, Gotshal & Manges
Law Firm
Garretts
Law Firm
Rothschild & Sons
Investment Bank
Arthur Andersen
Accountants
Beeson Gregory
Stockbroker
Customers
Glaxo Wellcome
Peptide Therapeutics
Lundbeck
Alizyme Plc
Febtuary 2001
TM
improves the business environment and interfaces between the industry and government
Activities and Mechanisms
Board of Directors
Febtuary 2001
TM
Industry
Representatives
Other Cluster
Representatives
Genzyme
MIT Office of
Technology
Transfer
Biogen
Venture
Capital
Genetics Institute
Massachusetts
General Hospital
Millenium
Arthur Andersen
Additional
Industry
Representatives
Additional Cluster
Representatives
Appoint a full time project leader or executive director to lead the implementation effort
Bring biotech on the national agenda and declare a clear vision for the industry
Form an intergovernmental task force to coordinate government policy
Attract an intl company and support Israeli companies which offer integrated services
and equipment in
Upgrade physical
infrastructure which
supports the
industry
Support applied
research and
technology transfer
processes
Febtuary 2001
TM
Reinforce regulatory
infrastructure
Map infrastructure
required to
support research
in academia
Implement tracking
system for industry
data and
performance
matrix
Set up world class scientific and business advisory board to support incubator projects
Increase funding and timing of projects to meet industry needs
Implement highly selective screening process for projects
Increase communication with the industry - clarify guidelines and information requirements
for clinical trials
Facilitate approval of phase 1 clinical trials through either a) stronger linkages with the FDA
(e.g. FDA affiliate office), or b) by adding resources to the health ministry
Add resources to the institute of standardization and control of pharmaceutical specialized
in biotechnology for evaluation and GMP accreditation
Map equipment requirements for academic research to ensure that Israels academia
maintains its position
Track data on industrial and research activity to facilitate networking and monitor
performance
Febtuary 2001
TM